CXCL10 acts on CD4 + and CD8 + T cells to enhance antitumor immunity, and the serum level of CXCL10 in breast cancer patients is positively correlated with tumor size and ER status [41, 42]. This evidence concerns the gene CD4 and breast carcinoma.